Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.

Keywords

Pravastatin, PCSK9, Internal medicine, Medicine, Single-nucleotide polymorphism

References

• The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in womenD. Gareth Evans, Frank Ulrich Beil — 2006
• Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study.Carlos Lahoz, Doreen Osgood, P W Wilson — 1996
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.Shirya Rashid, David E. Curtis, Rita Garuti — 2005
• Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.Erik Ingelsson, Ernst J. Schaefer, John H. Contois — 2007
• Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study.Carlos Lahoz, Ernst J. Schaefer, L. Adrienne Cupples — 2001
• Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.José M. Ordovás, José López‐Miranda, Francisco Pérez‐Jiménez — 1995
• Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin TherapyKnut Erik Berge, Leiv Ose, Trond P. Leren — 2006
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaMarianne Abifadel, Mathilde Varret, Jean‐Pierre Rabès — 2003
• Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver*Sahng Wook Park, Young-Ah Moon, Jay D. Horton — 2004
• Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Juan Pedro‐Botet, Ernst J. Schaefer, Rebecca Bakker‐Arkema — 2001
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.Jonathan C. Cohen, Eric Boerwinkle, Thomas H. Mosley — 2006
• Apolipoprotein E alleles and risk of coronary disease. A meta-analysis.Peter W.F. Wilson, Ernst J. Schaefer, Martin G. Larson — 1996
• The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationNabil G. Seidah, Suzanne Benjannet, L. Alexandra Wickham — 2003
• The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.J Shepherd, Gerard J. Blauw, Michael Murphy — 1999
• A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.Ingrid K. Kotowski, Alexander Pertsemlidis, Amy Luke — 2006
• A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.Suet N. Chen, Christie M. Ballantyne, Antonio M. Gotto — 2005
• NARC-1/PCSK9 and Its Natural MutantsSuzanne Benjannet, David Rhainds, Rachid Essalmani — 2004
• THE INTERACTION OF SELECTION AND LINKAGE. II. OPTIMUM MODELS.Richard C Lewontin — 1964
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.James Shepherd, Gerard J. Blauw, Michael Murphy — 2002
• Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial HypercholesterolemiaGeneviève Dubuc, Ann Chamberland, Hanny Wassef — 2004

Cited by

• Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.John Hamilton — 2014
• Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.Brian A. Ference, Wonsuk Yoo, Issa Alesh — 2012
• The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in HyperlipidemiaMichel Farnier — 2011
• Genes, inflammation, and age-related diseasesStella Trompet — 2009
• PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.Marianne Benn, Børge G. Nordestgaard, Peer Grande — 2010
• The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in TaiwanLung‐An Hsu, Ming‐Sheng Teng, Yu‐Lin Ko — 2009
• Combined PCSK9 and APOE Polymorphisms are Genetic Risk Factors Associated with Elevated Plasma Lipid Levels in a Thai PopulationNutjaree Jeenduang, Sureerut Porntadavity, Smith Wanmasae — 2015
• PCSK9 and LDL cholesterol: unravelling the target to design the bullet.Philippe Costet, Michel Krempf, Bertrand Cariou — 2008
• Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MIBas Peters, Helmi Pett, Olaf H. Klungel — 2011
• The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of AtherosclerosisJean Davignon, Geneviève Dubuc, Nabil G. Seidah — 2010
• Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol DrugsMarianne Abifadel, Sandy Elbitar, Petra El Khoury — 2014
• PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.A. David Marais, Jae B. Kim, Scott M. Wasserman — 2015
• Statin Pharmacogenomics: Lipid Response and Cardiovascular OutcomesTuomas Kerola, Terho Lehtimäki, Mika Kähönen — 2010
• Molecular basis of PCSK9 function.Gilles Lambert, Francesca Charlton, Kerry‐Anne Rye — 2009
• PCSK9 and its modulation.Chuan-Jue Cui, Sha Li, Jian‐Jun Li — 2015
• Polymorphisms of PTPN11 gene could influence serum lipid levels in a sex-specific patternZhifang Jia, Xueyuan Cao, Donghui Cao — 2013
• Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection StudyJemma C. Hopewell, Sarah Parish, Alison Offer — 2012
• Pharmacogenomics, Lipid Disorders, and Treatment OptionsSteven E. Gryn, Robert A. Hegele — 2014
• The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populationsLynn Htet Htet Aung, Rui‐Xing Yin, Lin Miao — 2011
• Potential of PCSK9 as a new target for the management of LDL cholesterolGiuliana Mombelli, Chiara Pavanello, S. Castelnuovo — 2015

Related papers

• Comparison of Fluvastatin and Pravastatin in Therapeutic Effect for HyperlipidemiaChen Shangr — 2002
• LDLR, PCSK9, and LDLRAP1 mutations in the same patient in a familial hypercholesterolemia (FH) family.Guido Cocci, Alessandra Cenci, Marica Bordicchia — 2017
• Molecular genetics of familial hypercholesterolemia in Israel - revisited.Durst Ronen, Uche Ken Ibe, Shpitzen Shoshi — 2017
• PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive SynopsisQianyun Guo, Xunxun Feng, Yujie Zhou — 2020
• Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia - A Post-Marketing Survey (J-POSSIBLE).Arihiro Kiyosue, Satoshi Yasuda, Akiyoshi Tomura — 2023
• A systematic review and meta-analysis of the efficacy of medications directed against PCSK9 in familial hypercholesterolemia.Julia Brandts, Kanika Dharmayat, Antonio J. Vallejo‐Vaz — 2021
• eP335: Genetic testing for APOB, LDLR, PCSK9, and LDLRAP1 suggest that FH testing may be underutilizedChristin Collins, Abhinav Mathur, Lavania Sharma — 2022
• Research progress of genetic causes of familial hypercholesterolemia(FH)Zhiqiang Lu — 2012
• Reduction of LDL-C levels with AMG-145, a monoclonal antibody against PCSK9, in heterozygous familial hypercholesterolemia: the RUTHERFORD studyDavid Rhainds, Jean‐Claude Tardif — 2013
• Characterization of the Effects of Familial Hypercholesterolemia Mutations in LDLR on PCSK9 BindingShijun Deng, Adekunle Alabi, Dawei Zhang — 2018